Nitric Oxide Synthesis Metabolites-As Potential Markers in Chronic Kidney Disease in Children

• Published in: Current issues in molecular biology 2022-08, Vol.44 (8), p.3518-3532
• Main Authors: Piechowicz, Joanna, Gamian, Andrzej, Chukwu, Ositadima, Polak-Jonkisz, Dorota
• Format: Article
• Language: English
• Subjects: asymmetric dimethylarginine; chronic renal failure; citrulline; nitric oxide metabolites; symmetric dimethylarginine
• ISSN: 1467-3045; 1467-3037; 1467-3045
• DOI: 10.3390/cimb44080242

Nitric oxide (NO) is an important signaling molecule for many physiological and pathological processes. Diseases associated with abnormal NO synthesis include cardiovascular diseases, insulin-dependent diabetes, or chronic kidney disease (CKD). The aim of the paper was to evaluate NO synthesis metabolites, i.e., asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), dimethylamine (DMA), arginine, citrulline in plasma of patients with different severity of CKD and to seek possible links between these parameters and the development of this disease. Forty-eight CKD children and thirty-three age-matched controls were examined. Patients were divided into groups depending on the CKD stages (Group II-stage II, Group III-stage III, Group IV-stage IV, and Group RRT children on dialysis). To determine the concentrations of the above-mentioned metabolites in plasma liquid chromatography-mass spectrometry was used. There were significant differences observed in levels of ADMA, SDMA, DMA, and citrulline between control vis CKD groups (p values ranging from